Source comparison
Melanotan-1 for Women Over 40: Comparison of Peptide Tanning Options
Before selecting a peptide protocol, understanding how melanotan-1 compares to alternative melanogenic compounds matters. Particularly when receptor selectivity, half-life, and adverse event profiles differ meaningfully. Melanotan-1 (Afamelanotide) High select
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, understanding how melanotan-1 compares to alternative melanogenic compounds matters. Particularly when receptor selectivity, half-life, and adverse event profiles differ meaningfully.
- Melanotan-1 (Afamelanotide)
- High selectivity for MC1R. Minimal binding to MC3R, MC4R, MC5R
- 30–50 minutes (subcutaneous)
- 10–21 days depending on baseline melanocyte density
- Nausea (15–25%), injection site reactions, flushing
- FDA-approved for EPP (Scenesse implant); research-grade available
- No age-stratified trials; mechanism supports efficacy but dosing adjustments for renal clearance recommended
- Melanotan-2
- Nonselective. Binds MC1R, MC3R, MC4R, MC5R
- 60–90 minutes
- 7–14 days; faster onset due to MC4R co-activation
- Nausea (40–60%), spontaneous erections, appetite suppression, increased libido
- Not FDA-approved; grey-market availability only
- Not recommended. MC4R agonism complicates cardiovascular risk in women over 40 with pre-existing hypertension
- Synthetic α-MSH Analogues
- Varies by structure; some are MC1R-selective, others are pan-agonists
- 20–40 minutes (highly dependent on peptide sequence modifications)
- 14–28 days
- Minimal GI effects; injection site inflammation more common
- Research-grade only; no approved formulations
- Limited data; mechanism is identical to melanotan-1 but purity and consistency vary widely across suppliers
- The bottom line: melanotan-1 is the only MC1R-selective agonist with an FDA-approved formulation and a decade of post-market safety data. Melanotan-2's nonselective receptor binding introduces appetite suppression, cardiovascular effects, and sexual side effects that complicate use in women over 40. Particularly those on antihypertensives, SSRIs, or HRT. Synthetic α-MSH analogues may offer similar melanogenic effects but lack the regulatory oversight and batch-to-batch consistency that Real Peptides ensures through small-batch synthesis and third-party purity verification. For research applications prioritising safety and reproducibility, melanotan-1 remains the standard.